AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Indivior settles patent dispute with Mylan over Suboxone.
ByAinvest
Sunday, Feb 2, 2025 1:22 pm ET1min read
Indivior has settled a patent dispute with Mylan related to generic versions of Suboxone, a treatment for opioid addiction. The settlement is confidential and does not affect the company's revenue, which is heavily reliant on Suboxone. The agreement resolves a long-standing legal battle between the two companies.
Indivior PLC, a global specialty pharmaceutical company, announced on September 25, 2017, that it had settled a patent dispute with Mylan Pharmaceuticals over generic versions of Suboxone, a treatment for opioid addiction [1]. The terms of the settlement, which resolved a long-standing legal battle between the two companies, are confidential.The litigation, which had been pending in the U.S. District Court for the District of Delaware, resulted from Mylan's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market generic versions of Suboxone Sublingual Film. Indivior's CEO, Shaun Thaxter, expressed his satisfaction with the settlement, stating that it reflected the company's commitment to protecting its intellectual property and creating certainty for Indivior [1].
Indivor is a leader in addiction treatment, with a 20-year legacy of advocacy and evidence-based treatment models [1]. The company's portfolio of opioid dependence treatments includes a strong pipeline of product candidates designed to expand its presence in this category and address other chronic conditions and co-occurring disorders of addiction [1].
The settlement does not affect Indivior's revenue, which is heavily reliant on Suboxone. In fact, the company recently received a new patent ('454) for Suboxone Film, further expanding its intellectual property estate for this product [1].
References:
[1] Indivior. (2017, September 25). Indivior enters into settlement with Mylan Pharmaceuticals. Retrieved from https://www.indivior.com/en/media/press-releases/indivior-enters-into-settlement-with-mylan-pharmaceuticals
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet